A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
GlaxoSmithKline
Valo Therapeutics Oy
BioEclipse Therapeutics
Celgene
Celgene
Novartis
INSYS Therapeutics Inc